Category 1: Medical CEO Patient Scripts · Episode 10

How to Ask Your Doctor for GLP-1 Maintenance Dosing

Clinical Answer Capsule: Discontinuing GLP-1 therapy upon reaching target weight triggers neuro-endocrine rebound: STEP-1 trial extension data confirms that patients regain two-thirds of lost weight and experience cardiometabolic marker regression within 52 weeks of cessation. Patients should negotiate ongoing maintenance protocols utilizing minimum effective dosages or extended 10-to-14-day injection intervals.
STEP-1 Trial ExtensionNeuro-Endocrine Rebound KineticsWeight Regain TelemetryCardiometabolic RegressionMaintenance Titration Schedule
Executive Action Script
"STEP-1 trial data demonstrates a two-thirds weight regain upon abrupt cessation. I request establishing a long-term maintenance protocol with spaced-out dosing intervals."

Full Video Dialogue & Clinical Context

If your doctor wants to pull you off your GLP-1 cold turkey the second you hit your goal weight, stop them right there. Stopping abruptly causes massive hunger rebound because chronic incretin deficiency doesn't just disappear. Ask them directly: 'What is our long-term maintenance protocol to space out shots or adjust dosage while keeping my metabolism stable?' Obesity is a chronic condition, not a temporary sentence. Grab the GLP-1 Maintenance & Deprescribing Guide at bitchesandbesties.com/armory.

🔬 Verified Clinical Reference:
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022; 24(8):1553-1564. PMID: 35482346
Access Study: https://pubmed.ncbi.nlm.nih.gov/35482346/
Featured Armory Instrument
Tool 02: The Medical CEO Appointment Planner & Lab Guide
Includes the Long-Term Care & Spaced Titration Schedule to manage post-goal maintenance without triggering acute incretin withdrawal.
Unlock Free Instrument in The Armory →